Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors.


Despite the use of the sirolimus (rapamycin) drug-eluting coronary stent, diabetics are at increased risk of developing in-stent restenosis for unclear reasons. Hyperleptinemia, which often coexists with diabetes and metabolic syndrome, is an independent risk factor for progression of coronary artery disease. It has not been determined whether elevated… (More)
DOI: 10.1073/pnas.0809743105


5 Figures and Tables